Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,228 questions · 1,245 findings · 383 reviews

No studies found 403 · 32.4%GRADE not reported 128 · 10.3%Very low 385 · 30.9%Low 232 · 18.6%Moderate 81 · 6.5%High 16 · 1.3%

Intervention not reported

Serious adverse events ‐ not measured · patients with acute gout

The review found no eligible studies for this question.

1 finding from 1 review

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs sdNVP plus ZDV (1 week)

Infants with Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers

It is very uncertain whether an extended NVP plus ZDV regimen administered to infants for 14 weeks changes infants with any Severe Adverse Events compared with sdNVP plus ZDV (1 week) (very low certainty).

1 finding from 1 review

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

Infants with Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers

An extended NVP plus ZDV dual regimen administered to infants for 14… may leads to higher infants with any Severe Adverse Events compared with an extended NVP regimen administered to infants (low certainty).

1 finding from 1 review

Fexofenadine 120 mg/d vs placebo (1‐week intervention)

Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema

Fexofenadine 120 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (1‐week intervention) (moderate certainty).

1 finding from 1 review